来源：市场资讯 （来源：写意宣发） 10月31日，辉瑞宣布美国联邦贸易委员会已批准根据经修订的1976年《哈特-斯科特-罗地诺反垄断改进 法案》（"HSR法案"），提前终止辉瑞即将收购Metsera（NASDAQ:MTSR）的等待期。根据HSR法案 终止等待期符合之前宣布的收购Metsera的监管审查要求，该收购将于11月7日到期。 同时，辉瑞宣布已向特拉华州衡平法院（Delaware Court of Chancery）提起诉讼，起诉Metsera及其董事 会和Novo Nordisk。该诉讼声称，由于Metsera违反了辉瑞和Metsera之间的合并协议规定的义务，因此 违反了合同、违反了信托责任和侵权干涉合同。 辉瑞声称根据合并协议的条款，诺和诺德的报价不符合"Superior Company Proposal"的条件，包括因为 相对于辉瑞的交易，考虑到提案的重大监管风险，诺和诺德的交易不太可能按照拟议的条款完成。相比 之下，今天美国联邦贸易委员会根据经修订的1976年《哈特-斯科特-罗迪诺反垄断改进法案》，就辉瑞 即将收购Metsera一事，提前终止了等待期。辉瑞收购Metsera的所有监管批准均已获 ...

Core Viewpoint - Metsera, Inc. has issued a statement in response to litigation filed by Pfizer, asserting disagreement with the allegations and indicating plans to address them in court [1]. Company Response to Litigation - Metsera disagrees with the allegations made in Pfizer's complaint and will respond in the Delaware Court of Chancery [1]. Proposed Acquisition Details - The statement includes forward-looking information regarding Pfizer's proposed acquisition of Metsera, highlighting potential benefits and risks associated with the acquisition process [1]. - The acquisition is subject to various risks, including litigation expenses, potential damages, and the impact on Metsera's business and stock price [1]. Regulatory and Approval Considerations - The completion of the proposed acquisition depends on satisfying conditions such as obtaining necessary regulatory approvals and the requisite vote from Metsera's stockholders [1]. - There is a possibility that the acquisition may not close or that competing offers may arise [1]. Market and Business Impact - The announcement of the litigation and the proposed acquisition could negatively affect the market price of both Pfizer's and Metsera's common stock [1]. - The integration of businesses post-acquisition may face challenges, impacting operational relationships and the ability to retain qualified personnel [1]. Pipeline Products and Clinical Trials - The statement discusses Metsera's pipeline products and the associated risks, including the potential for adverse events and the uncertainties inherent in clinical trials [1]. - Metsera's reliance on third parties for clinical trials and product manufacturing is also noted as a risk factor [1].

Pfizer said US regulators have cleared it to proceed with its offer to acquire obesity startup Metsera, upping the pressure on Novo, which is attempting to make a rival bid https://t.co/4BuaCavETR ...

TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky OctoberPfizer (PFE) sued Metsera (MTSR) and Novo Nordisk (NVO) on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused biotech company.The move is the second jab in an escalating battle pitting Pfizer and Novo Nordisk. The first came Thursday when Novo issued an unsolicited bid to buy Metsera, a month after Pfizer struck a deal to acquire Metsera for $4.9 billion.Pfizer's lawsuit asserts that Metsera breached ...

(Reuters) -Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker's $8.5 billion bid for the U.S. obesity drug developer to be a superior offer. Pfizer asked the Delaware court where it filed the lawsuit to issue a temporary restraining order to block Metsera from terminating the agreement. The lawsuit was not immediately available in the court's electronic filing system. Metsera has given ...

The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed. ...

(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer. Metsera has declared Novo's offer superior, and given Pfizer until Tuesday to raise its bid. The U.S. Federal Trade Commission granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews. The waiting period was originally set to e ...

Group 1 - Pfizer has filed a lawsuit against Metsera and Novo Nordisk for allegedly breaching a merger agreement [1] - The lawsuit claims that Metsera and Novo Nordisk interfered with the merger deal [1]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera. Pfizer alleges that the Novo Nordisk offer cannot qualify as a "Superior Company Proposal†u. ...

Key TakeawaysMajor U.S. stock indices closed higher, with the Dow Jones up 0.15%, the S&P 500 gaining 0.31%, and the Nasdaq leading the rally with a 0.70% increase.Pfizer (PFE) received early U.S. Federal Trade Commission (FTC) clearance for its Metsera acquisition, a crucial step forward in its strategy to enter the rapidly growing obesity drug market.Johnson & Johnson (JNJ) submitted an application to the U.S. FDA for Stelara® (ustekinumab) for the treatment of pediatric ulcerative colitis, aiming to expa ...